Matthew M. Miele

Matthew M. Miele

Auto-generated profile, based on publicly available information

Matthew M. Miele

Proteomics Core, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in Nature
Verified
Journal Article
Open access
PDF file
HWHua Wang
Hua Wang
ZFZheng Fan
Zheng Fan
PSPavel V. Shliaha
Pavel V. Shliaha
MMMatthew Miele
Matthew Miele
RHRonald C. Hendrickson
Ronald C. Hendrickson
KHKristian Helin
Kristian Helin
Trimethylation of histone H3 lysine 4 (H3K4me3) is associated with transcriptional start sites and has been proposed to regulate transcription initiation1,2. However, redundant functions of the H3K4 SET1/COMPASS methyltransferase complexes complicate the elucidation of the specific role of H3K4me3 in transcriptional regulation3,4. Here, using mouse embryonic stem cells as a model system, we show that acute ablation of shared subunits of the SET1/COMPASS complexes leads to a complete loss of all H3K4 methylation. Turnover of H3K4me3 occurs more rapidly than that of H3K4me1 and H3K4me2 and is dependent on KDM5 demethylases. Notably, acute loss of H3K4me3 does not have detectable effects on transcriptional initiation but leads to a widespread decrease in transcriptional output, an increase in RNA polymerase II (RNAPII) pausing and slower elongation. We show that H3K4me3 is required for the recruitment of the integrator complex subunit 11 (INTS11), which is essential for the eviction of paused RNAPII and transcriptional elongation. Thus, our study demonstrates a distinct role for H3K4me3 in transcriptional pause-release and elongation rather than transcriptional initiation.

15 December 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
DRDivya Ramchandani
Divya Ramchandani
MBMirela Berisa
Mirela Berisa
DTDiamile A. Tavarez
Diamile A. Tavarez
ZLZhuoning Li
Zhuoning Li
MMMatthew Miele
Matthew Miele
VMVivek Mittal
Vivek Mittal
Copper serves as a co-factor for a host of metalloenzymes that contribute to malignant progression. The orally bioavailable copper chelating agent tetrathiomolybdate (TM) has been associated with a significant survival benefit in high-risk triple negative breast cancer (TNBC) patients. Despite these promising data, the mechanisms by which copper depletion impacts metastasis are poorly understood and this remains a major barrier to advancing TM to a randomized phase II trial. Here, using two independent TNBC models, we report a discrete subpopulation of highly metastatic SOX2/OCT4+ cells within primary tumors that exhibit elevated intracellular copper levels and a marked sensitivity to TM. Global proteomic and metabolomic profiling identifies TM-mediated inactivation of Complex IV as the primary metabolic defect in the SOX2/OCT4+ cell population. We also identify AMPK/mTORC1 energy sensor as an important downstream pathway and show that AMPK inhibition rescues TM-mediated loss of invasion. Furthermore, loss of the mitochondria-specific copper chaperone, COX17, restricts copper deficiency to mitochondria and phenocopies TM-mediated alterations. These findings identify a copper-metabolism-metastasis axis with potential to enrich patient populations in next-generation therapeutic trials.

13 January 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JMJorge Mansilla-Soto
Jorge Mansilla-Soto
JEJustin Eyquem
Justin Eyquem
SHSascha Haubner
Sascha Haubner
MHMohamad Hamieh
Mohamad Hamieh
JFJudith Feucht
Judith Feucht
MSMichel Sadelain
Michel Sadelain

13 July 2020 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
JYJiang Yang
Jiang Yang
TWTai Wang
Tai Wang
LZLina Zhao
Lina Zhao
VRVinagolu K. Rajasekhar
Vinagolu K. Rajasekhar
SJSuhasini Joshi
Suhasini Joshi
MKMoritz F. Kircher
Moritz F. Kircher

18 September 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
ASAlexander H. Settle
Alexander H. Settle
BWBenjamin Y. Winer
Benjamin Y. Winer
MJMiguel M. de Jesus
Miguel M. de Jesus
LSLauren Seeman
Lauren Seeman
ZWZhaoquan Wang
Zhaoquan Wang
MHMorgan Huse
Morgan Huse
Phagocytosis is an intensely physical process that depends on the mechanical properties of both the phagocytic cell and its chosen target. Here, we employed differentially deformable hydrogel microparticles to examine the role of cargo rigidity in the regulation of phagocytosis by macrophages. Whereas stiff cargos elicited canonical phagocytic cup formation and rapid engulfment, soft cargos induced an architecturally distinct response, characterized by filamentous actin protrusions at the center of the contact site, slower cup advancement, and frequent phagocytic stalling. Using phosphoproteomics, we identified β2 integrins as critical mediators of this mechanically regulated phagocytic switch. Macrophages lacking β2 integrins or their downstream effectors, Talin1 and Vinculin, exhibited specific defects in phagocytic cup architecture and selective suppression of stiff cargo uptake. We conclude that integrin signaling serves as a mechanical checkpoint during phagocytosis to pair cargo rigidity to the appropriate mode of engulfment.

4 June 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
YCYanyan Cai
Yanyan Cai
PZPeihua Zhao
Peihua Zhao
FWFan Wu
Fan Wu
HZHuiyong Zhao
Huiyong Zhao
HSHong Shao
Hong Shao
SCSarat Chandarlapaty
Sarat Chandarlapaty
Endocrine resistance is frequently encountered in estrogen receptor–positive (ER+) breast cancer, often because of somatic mutations such as neurofibromin 1 ( NF1 ) loss. The mechanisms by which ER-directed proliferation is lost in such cases are unknown, limiting the potential use of additional endocrine treatments. Here, we performed CRISPR-Cas9 knockout (KO) screens and found that nuclear receptor subfamily 2 group F member 2 (NR2F2), an orphan nuclear receptor, was essential for NF1 loss–induced endocrine resistance. Induction of NR2F2 was observed in ER+ cell line models and patient samples and occurred via activation of the mitogen-activated protein kinase (MAPK) pathway upon NF1 loss or other MAPK pathway genetic alterations. Mechanistically, increased NR2F2 orchestrated a repressed ER transcriptional program by repartitioning the ER cistrome, altering the balance of its associated transcriptional coregulators, and modifying global chromatin accessibility. Accordingly, genetic depletion or pharmacologic inhibition of NR2F2 restored sensitivity to hormone therapies in multiple models, including ER+ cell lines, patient-derived xenografts, and patient-derived organoid-based xenografts harboring diverse endocrine-resistance mechanisms such as NF1 , AT-rich interactive domain-containing protein 1A ( ARID1A ), phoshatase and tensin homolog ( PTEN ) loss, or Kirsten rat sarcoma virus ( KRAS ) overexpression. Together, these findings underscore NR2F2 as a critical modulator of the hormone response pathway and suggest its inhibition as a promising strategy to overcome endocrine resistance in breast cancer.